X4 Pharmaceuticals XFOR Cash Flow Statement (2017-2026)

NASDAQ XFOR
$4.04 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT
Reported Financials

X4 Pharmaceuticals Quarterly Cash Flow Statement

Periods 38 quarters
Latest Jun 2026

X4 Pharmaceuticals reported cash from operations of -$20.80M and free cash flow of -$20.80M for the quarter ended Jun 2026, up 30.4% year over year. This cash flow statement covers 38 quarters of results from Mar 2017 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-20.18M-30.21M-21.96M-21.21M-21.59M-29.10M-24.02M-55.71M-2.31M-19.13M-51.77M90.83M-36.70M-39.82M0.28M-25.74M-29.82M-23.93M-20.24M-16.16M
Share-based CompensationStock Comp.
1.52M1.61M1.46M1.52M1.11M1.11M1.65M2.14M2.36M2.54M1.74M2.43M1.82M2.22M0.52M0.75M0.76M2.27M2.41M3.09M
Gains from Investment SecuritiesGains Investment
-5.44M29.86M-25.16M13.76M-20.21M1.86M
Cash from OperationsCash from Ops.
-14.21M-19.05M-20.23M-18.47M-19.31M-19.09M-26.51M-47.90M-68.80M-27.75M-33.60M-63.90M-34.03M-32.99M-12.37M-29.90M-27.83M-15.52M-19.60M-20.80M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
0.13M0.13M0.13M0.13M0.12M0.12M0.13M0.13M0.10M0.06M0.06M0.19M0.27M0.27M0.48M0.35M0.22M0.22M0.22M1.00M
Change in Working Capital
Change in ReceivablesChange Receivables
1.07M-0.56M0.64M-0.25M-0.32M0.54M0.93M
Change in InventoryChange Inventory
0.83M1.61M0.37M0.27M0.08M0.91M0.40M0.16M0.86M
Change in Account PayablesChange Payables
-0.10M1.86M-0.71M0.11M0.12M3.91M-1.71M-1.10M3.24M0.81M0.00M-0.95M0.58M0.08M2.48M-3.44M-2.65M0.64M-0.62M-1.14M
Change in Accured ExpensesChange Accured Exp.
1.92M-1.22M-0.98M1.64M0.65M2.50M0.50M4.53M0.63M-4.04M1.26M2.74M-0.17M3.34M-7.78M0.23M3.37M2.17M-1.55M-2.93M
Other Working Capital ChangesOther WC Changes
1.81M-0.23M-0.20M-0.30M-0.06M0.41M
Investing Activities
Capital ExpendituresCapex
0.02M0.01M0.02M0.04M0.01M0.03M0.01M0.01M0.01M0.04M0.06M3.44M0.50M
Change in IntangiblesChange Intangibless
Acquisitions
Change in Acquisitions & DivestmentsChange Acquisitions
1.00M1.00M5.00M2.00M5.25M14.20M11.75M28.18M15.87M18.75M19.25M4.00M
Cash from Investing ActivitiesCash from Investing
-0.02M-0.01M-0.02M-0.04M-0.01M-0.03M-0.01M-4.88M-5.16M-4.83M-5.32M96.86M-15.93M-8.62M-3.14M23.11M-28.67M16.85M19.25M-1.00M
Financing Activities
Other financing activitiesOther financing
0.14M0.05M0.05M0.00M0.07M
Cash from Financing ActivitiesCash from Financing
-4.44M24.57M4.96M-0.35M51.98M60.64M-2.12M69.34M21.20M0.10M20.16M0.14M5.63M86.91M146.09M0.00M0.07M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
0.00M51.38M86.91M146.04M
Additional items
Exchange Rate EffectFX Effect
-0.10M-0.12M-0.07M-0.20M-0.20M0.36M0.05M-0.01M-0.07M0.13M-0.06M-0.02M0.17M-0.24M0.07M0.14M-0.00M0.00M-0.02M-0.01M
Change in Cash
-18.77M5.39M-15.36M-19.06M32.47M41.88M-28.59M43.02M-4.85M-32.36M-38.98M86.73M-49.80M-41.73M-15.43M-1.02M30.41M147.42M-0.36M-21.72M
Free Cash FlowFCF
-14.23M-19.07M-20.25M-18.51M-19.32M-19.13M-26.52M-47.91M-68.81M-27.78M-33.66M-67.34M-34.03M-32.99M-12.37M-29.90M-27.83M-16.02M-19.60M-20.80M
Net Cash FlowNCF
-18.67M5.50M-15.29M-18.86M32.66M41.52M-28.64M16.55M-52.75M-32.48M-38.92M53.12M-49.96M-41.48M-15.51M-1.16M30.41M147.42M-0.35M-21.73M